{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:37:47Z","timestamp":1782869867055,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Vandetanib is effective for treating symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease, but its toxicity such as photosensitivity reactions should be considered. It is a rare adverse effect of this drug but might cause severe morbidity and even mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 26-year man with MTC developed phototoxic rashes on the sun-exposed areas of his shin after 15 days from the initiation of vandetanib treatment. Grade II skin toxicity was evaluated based on the Common Terminology Criteria for Adverse Events standard.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Drug-induced phototoxic rash.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The vandetanib dose was reduced by 30%, and the application of topical steroids and sunscreen was adopted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After dose reduction of vandetanib, the symptoms of vandetanib-induced phototoxic rash resolved, although residual pigmentation was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Close attention should be paid to the adverse effect of vandetanib, phototoxic rash, and patients should be advised on the prevention and treatment measures.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016392","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T16:34:37Z","timestamp":1564763677000},"page":"e16392","source":"Crossref","is-referenced-by-count":14,"title":["A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer"],"prefix":"10.1097","volume":"98","author":[{"given":"Yue","family":"Yin","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Ye","family":"Qiu","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1038\/srep08629","article-title":"The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci Rep"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2015.04.004","article-title":"Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases","volume":"89","author":"Subbiah","year":"2015","journal-title":"Lung Cancer"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.canlet.2007.12.001","article-title":"EGFR and VEGFR as potential target for biological therapies in HCC cells","volume":"262","author":"Giannelli","year":"2008","journal-title":"Cancer Lett"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100\u200amg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1200\/JCO.2007.12.3083","article-title":"Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","volume":"25","author":"Arnold","year":"2007","journal-title":"J Clin Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"key":"R13-20230914","first-page":"271","article-title":"Epidermal cell kinetics of the pig: a review","volume":"23","author":"Morris","year":"1990","journal-title":"Cell Tissue Kinet"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/2013.jamadermatol.192","article-title":"A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib","volume":"148","author":"Giacchero","year":"2012","journal-title":"Arch Dermatol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.5021\/ad.2011.23.S3.S343","article-title":"Stevens-johnson syndrome induced by vandetanib","volume":"23","author":"Yoon","year":"2011","journal-title":"Ann Dermatol"},{"issue":"(27 (September 20))","key":"R17-20230914","first-page":"e114","article-title":"Severe Photosensitivity Reaction to Vandetanib","volume":"27","author":"Chih-Hsiang","year":"2009","journal-title":"J Clin Oncol"},{"key":"R19-20230914","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"e5172","DOI":"10.1371\/journal.pone.0005172","article-title":"Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function","volume":"4","author":"Zhen","year":"2009","journal-title":"PLos One"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0190-9622(96)90108-5","article-title":"Drug photosensitivity, idiopathic photodermatoses, and sunscreens","volume":"35","author":"Gonz\u00e1lez","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R23-20230914","first-page":"1066","article-title":"Abnormal responses to ultraviolet radiation: photosensitivity induced by exogenous agents.","author":"Lim","year":"2014","journal-title":"Fitzpatrick's Dermatology in General Medicine"},{"key":"R24-20230914","first-page":"394","article-title":"The photosensitivity disorders.","author":"Calonge","year":"2014","journal-title":"Lever's Histopathology of the Skin"},{"issue":"(Suppl 3)","key":"R25-20230914","first-page":"S314","article-title":"Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel","volume":"23","author":"Young-Min Son","year":"2011","journal-title":"Ann Dermatol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1529-8019.2003.01601.x","article-title":"Classification and evaluation of photodermatoses","volume":"16","author":"Yashar","year":"2003","journal-title":"Dermatol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201908020-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:43:39Z","timestamp":1694720619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201908020-00004"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":23,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016392","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}